---
title: "Trulicity (dulaglutide) in type 2 diabetes: Indication questions"
description: "Indication questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Trulicity approved for? Is Trulicity approved to lower cardiovascular risk without established heart disease? Is Trulicity approved for weight loss? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Indication questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Indication questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications: Indication](https://www.evicenter.com/medical-information/trulicity/indication).

## Indication

<a id="trulicity-indication"></a>

### What is Trulicity approved for?

Applies to: Glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “TRULICITY® is indicated:
>
> As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
> To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%C2%AE%20is%20indicated%3A,or%20multiple%20cardiovascular%20risk%20factors.)

<a id="trulicity-cv-indication-primary-prevention"></a>

### Is Trulicity approved to lower cardiovascular risk without established heart disease?

Applies to: Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

> “Trulicity is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus<sup>1</sup>:
>
> Without established cardiovascular disease (CVD) who have multiple CV risk factors
> With established CVD”

Source: [TRULICITY: Trulicity for Cardiovascular | REWIND Trial, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/cardiovascular-disease#:~:text=Trulicity%20is%20indicated%20to%20reduce,With%20established%20CVD)

> “Patients eligible to enter the trial were 50 years of age or older who had type 2 diabetes mellitus, had an HbA1c value ≤9.5% with no lower limit at screening, and had either established CV disease, or did not have established CV disease but had multiple CV risk factors. Patients who were confirmed to have established CV disease (31.5% of randomized patients) had a history of at least one of the following: MI (16.2%); myocardial ischemia by a stress test or with cardiac imaging (9.3%); ischemic stroke (5.3%); coronary, carotid, or peripheral artery revascularization (18.0%); unstable angina (5.9%); or hospitalization for unstable angina with at least one of the following: ECG changes, myocardial ischemia on imaging, or a need for percutaneous coronary intervention (12.0%). Patients confirmed to be without established CV disease, but with multiple CV risk factors, comprised 62.8% of the randomized trial population.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Patients%20eligible%20to%20enter%20the,of%20the%20randomized%20trial%20population.)

Note: The second passage is from the description of the REWIND cardiovascular outcomes trial in the Prescribing Information.

<a id="trulicity-weight-loss-indication"></a>

### Is Trulicity approved for weight loss?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Trulicity is not indicated for weight loss. In clinical studies, weight change was a secondary endpoint.”

Source: [TRULICITY: Trulicity & Weight Loss | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing#:~:text=Trulicity%20is%20not%20indicated%20for,change%20was%20a%20secondary%20endpoint.)

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
